AKT1 and neoplasm: In the current studies using tumor xenograft models established with the trastuzumab-resistant BC sublines, we observed a marked increase of p-Akt in BT474-HR20-derived tumors (Fig. 5A left), which were refractory to lapatinib treatment (Fig. 3A).